Literature DB >> 21330365

Terminal N-linked galactose is the primary receptor for adeno-associated virus 9.

Shen Shen1, Kelli D Bryant, Sarah M Brown, Scott H Randell, Aravind Asokan.   

Abstract

Sialylated glycans serve as cell surface attachment factors for a broad range of pathogens. We report an atypical example, where desialylation increases cell surface binding and infectivity of adeno-associated virus (AAV) serotype 9, a human parvovirus isolate. Enzymatic removal of sialic acid, but not heparan sulfate or chondroitin sulfate, increased AAV9 transduction regardless of cell type. Viral binding and transduction assays on mutant Chinese hamster ovary (CHO) cell lines defective in various stages of glycan chain synthesis revealed a potential role for core glycan residues under sialic acid in AAV9 transduction. Treatment with chemical inhibitors of glycosylation and competitive inhibition studies with different lectins suggest that N-linked glycans with terminal galactosyl residues facilitate cell surface binding and transduction by AAV9. In corollary, resialylation of galactosylated glycans on the sialic acid-deficient CHO Lec2 cell line with different sialyltransferases partially blocked AAV9 transduction. Quantitative analysis of AAV9 binding to parental, sialidase-treated or sialic acid-deficient mutant CHO cells revealed a 3-15-fold increase in relative binding potential of AAV9 particles upon desialylation. Finally, pretreatment of well differentiated human airway epithelial cultures and intranasal instillation of recombinant sialidase in murine airways enhanced transduction efficiency of AAV9 by >1 order of magnitude. Taken together, the studies described herein provide a molecular basis for low infectivity of AAV9 in vitro and a biochemical strategy to enhance gene transfer by AAV9 vectors in general.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330365      PMCID: PMC3075699          DOI: 10.1074/jbc.M110.210922

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor.

Authors:  C Hundt; J M Peyrin; S Haïk; S Gauczynski; C Leucht; R Rieger; M L Riley; J P Deslys; D Dormont; C I Lasmézas; S Weiss
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

2.  Mechanism of galactosylation in the Golgi apparatus. A Chinese hamster ovary cell mutant deficient in translocation of UDP-galactose across Golgi vesicle membranes.

Authors:  S L Deutscher; C B Hirschberg
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

3.  Translocation across Golgi vesicle membranes: a CHO glycosylation mutant deficient in CMP-sialic acid transport.

Authors:  S L Deutscher; N Nuwayhid; P Stanley; E I Briles; C B Hirschberg
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

4.  The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues.

Authors:  W C Wang; R D Cummings
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

5.  The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence.

Authors:  N Shibuya; I J Goldstein; W F Broekaert; M Nsimba-Lubaki; B Peeters; W J Peumans
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

6.  Frontal affinity chromatography of ovalbumin glycoasparagines on a concanavalin A-sepharose column. A quantitative study of the binding specificity of the lectin.

Authors:  Y Ohyama; K Kasai; H Nomoto; Y Inoue
Journal:  J Biol Chem       Date:  1985-06-10       Impact factor: 5.157

7.  Control of carbohydrate processing: the lec1A CHO mutation results in partial loss of N-acetylglucosaminyltransferase I activity.

Authors:  P Stanley; W Chaney
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

8.  Swainsonine: an inhibitor of glycoprotein processing.

Authors:  A D Elbein; R Solf; P R Dorling; K Vosbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

9.  Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation.

Authors:  Laura T Martin; Jamey D Marth; Ajit Varki; Nissi M Varki
Journal:  J Biol Chem       Date:  2002-06-14       Impact factor: 5.157

10.  Structural requirements for the binding of oligosaccharides and glycopeptides to immobilized wheat germ agglutinin.

Authors:  K Yamamoto; T Tsuji; I Matsumoto; T Osawa
Journal:  Biochemistry       Date:  1981-09-29       Impact factor: 3.162

View more
  126 in total

Review 1.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

Review 2.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 3.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

4.  Capsid antibodies to different adeno-associated virus serotypes bind common regions.

Authors:  Brittney L Gurda; Michael A DiMattia; Edward B Miller; Antonette Bennett; Robert McKenna; Wendy S Weichert; Christian D Nelson; Wei-jun Chen; Nicholas Muzyczka; Norman H Olson; Robert S Sinkovits; John A Chiorini; Sergei Zolotutkhin; Olga G Kozyreva; R Jude Samulski; Timothy S Baker; Colin R Parrish; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

5.  Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors.

Authors:  S A Hoyng; F De Winter; S Gnavi; L van Egmond; C L Attwell; M R Tannemaat; J Verhaagen; M J A Malessy
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

6.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.

Authors:  William A Liguore; Jacqueline S Domire; Dana Button; Yun Wang; Brett D Dufour; Sathya Srinivasan; Jodi L McBride
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

Review 7.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

8.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

9.  Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.

Authors:  Prasad R Konkalmatt; Feng Wang; Bryan A Piras; Yaqin Xu; Daniel M O'Connor; Ronald J Beyers; Frederick H Epstein; Brian H Annex; John A Hossack; Brent A French
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

10.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.